Healthcare Industry News: Solvay Pharmaceuticals
News Release - June 1, 2009
Depomed Names Shay Weisbrich Vice President of MarketingMENLO PARK, Calif.--(HSMN NewsFeed)--Depomed, Inc. (NASDAQ:DEPO ) announced today that Shay Weisbrich has joined to the company as vice president of marketing. Ms. Weisbrich’s role will be to lead all marketing activities for the company’s current commercial products, provide commercial guidance to future products and commercial leadership in overseeing Depomed’s brand strategy. This will include strategic product selection, commercial development, and marketing of Depomed’s products.
Ms. Weisbrich has over 30 years of extensive experience in U.S. and global pharmaceutical companies with roles in marketing, sales and business development, including commercial guidance of Phases 1 – 4 development, product launches, strategic planning, portfolio planning, building of teams and infrastructure, and cross-functional team leadership. Her therapeutic area experience includes women’s health, diabetes, cardiovascular, CNS, HIV, dermatology and other specialty areas. Ms. Weisbrich spent over 20 years at Pharmacia & Upjohn (now Pfizer) with her most recent role as Global Director, Strategic Marketing, Women’s Health Care until 1997. She then assumed a number of vice president positions in areas such as marketing, sales and business development at Novo Nordisk, KV Pharmaceutical/Ther-Rx Corporation, Gilead Sciences, and most recently CV Therapeutics. She was also the General Manager, Diabetes marketing at Takeda North America.
“I am excited that Shay is joining the Depomed team. Shay has the experience and drive to help us reach the next step of Depomed’s corporate development as a specialty pharmaceutical company, and execute on our vision to achieve profitability by developing a broad women’s health franchise. The Depomed team and I found her to be a bright and energetic person , a good listener, an empathetic partner and a creative problem solver. We look forward to working with her and placing the responsibility for the marketing of our top assets into her hands,” said Carl A. Pelzel, president and chief executive officer of Depomed.
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate Serada is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.
The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to our clinical development programs; potential benefits of our products and product candidates; our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.